VOLUME 5 (2014)
Table of Contents
Reviews
|
| Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability |
|
https://doi.org/10.18632/oncotarget.1784
|
| 860-871 |
Priority Research Papers
|
| Genomewide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 DRD2 and epidermal growth factor receptor EGFR in glioblastoma |
|
https://doi.org/10.18632/oncotarget.1801
|
| 882-893 |
|
| Role of aberrant PI3K pathway activation in gallbladder tumorigenesis |
|
https://doi.org/10.18632/oncotarget.1808
|
| 894-900 |
|
| A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts |
|
https://doi.org/10.18632/oncotarget.1809
|
| 901-907 |
Research Papers
|
| A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS9973 a novel spleen tyrosine kinase Syk inhibitor |
|
https://doi.org/10.18632/oncotarget.1484
|
| 908-915 |
|
| Clinical impact of gene mutations and lesions detected by SNParray karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA0701 trial |
|
https://doi.org/10.18632/oncotarget.1536
|
| 916-932 |
|
| High Mdm4 levels suppress p53 activity and enhance its halflife in acute myeloid leukaemia |
|
https://doi.org/10.18632/oncotarget.1559
|
| 933-943 |
|
| Epigenetic silencing of microRNA199b5p is associated with acquired chemoresistance via activation of JAG1Notch1 signaling in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.1458
|
| 944-958 |
|
| Engineered repressors are potent inhibitors of androgen receptor activity |
|
https://doi.org/10.18632/oncotarget.1360
|
| 959-969 |
|
| LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer |
|
https://doi.org/10.18632/oncotarget.1630
|
| 970-977 |
|
| WNTpathway components as predictive markers useful for diagnosis prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer |
|
https://doi.org/10.18632/oncotarget.1571
|
| 978-992 |
|
| Posttranscriptional regulation of MRE11 expression in muscleinvasive bladder tumours |
|
https://doi.org/10.18632/oncotarget.1627
|
| 993-1003 |
|
| Repression of PLA2R1 by cMYC and HIF2alpha promotes cancer growth |
|
https://doi.org/10.18632/oncotarget.1681
|
| 1004-1013 |
|
| Indirect targeting of IGF receptor signaling in vivo by substrateselective inhibition of PAPPA proteolytic activity |
|
https://doi.org/10.18632/oncotarget.1629
|
| 1014-1025 |
|
| SCFβTRCPmediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway |
|
https://doi.org/10.18632/oncotarget.1675
|
| 1026-1037 |
|
| Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL6 STAT3 and the AHR |
|
https://doi.org/10.18632/oncotarget.1637
|
| 1038-1051 |
|
| Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epidriver gene |
|
https://doi.org/10.18632/oncotarget.1697
|
| 1052-1061 |
|
| Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.1760
|
| 1062-1070 |
|
| SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade |
|
https://doi.org/10.18632/oncotarget.1783
|
| 1071-1082 |
|
| miR17/20 sensitization of breast cancer cells to chemotherapyinduced apoptosis requires Akt1 |
|
https://doi.org/10.18632/oncotarget.1804
|
| 1083-1090 |
|
| HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFRalpha activation |
|
https://doi.org/10.18632/oncotarget.1787
|
| 1091-1100 |
|
| Functional analysis of MKP1 and MKP2 in breast cancer tamoxifen sensitivity |
|
https://doi.org/10.18632/oncotarget.1795
|
| 1101-1115 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
